Jakafi u's sales?

See the DrugPatentWatch profile for Jakafi

Jakafi (ruxolitinib) sales: how much revenue does it generate?

Jakafi (ruxolitinib) is a blockbuster drug, and the most commonly reported “sales” figures are its annual net product sales (often reported in company earnings). However, the specific dollar numbers for “Jakafi U.S. sales” are not included in the information provided here.

What people usually mean by “Jakafi U.S. sales” (and how to find the right number)

In searches like “Jakafi u’s sales,” people often want one of these:
- U.S. net product sales (revenue from prescriptions dispensed/charged in the U.S.)
- Worldwide sales (global revenue, sometimes mistaken as U.S. sales)
- Quarterly sales (latest quarter vs. full-year)

To pull the correct figure, you typically check:
- The manufacturer’s quarterly and annual financial releases (net product sales by geography if disclosed)
- Earnings call materials and investor presentations

If you meant “who sells it” and “what company reports the numbers?”

Jakafi is marketed in the U.S. by Incyte. Its reported sales figures come through Incyte’s financial reporting.

Want me to report the exact U.S. sales number for a specific year/quarter?

If you tell me the year or quarter you care about (for example, “2023 full year” or “Q1 2024”), I can format the answer around that period and clarify whether you want U.S.-only net product sales or worldwide sales.